EA004543B1 - Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови - Google Patents
Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови Download PDFInfo
- Publication number
- EA004543B1 EA004543B1 EA200200535A EA200200535A EA004543B1 EA 004543 B1 EA004543 B1 EA 004543B1 EA 200200535 A EA200200535 A EA 200200535A EA 200200535 A EA200200535 A EA 200200535A EA 004543 B1 EA004543 B1 EA 004543B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- use according
- treosulfan
- body surface
- days
- pharmaceutical composition
- Prior art date
Links
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 title abstract description 44
- 229960003181 treosulfan Drugs 0.000 title abstract description 44
- 230000003750 conditioning effect Effects 0.000 title abstract description 18
- 210000001185 bone marrow Anatomy 0.000 title abstract description 5
- 210000004369 blood Anatomy 0.000 title description 2
- 239000008280 blood Substances 0.000 title description 2
- 238000011476 stem cell transplantation Methods 0.000 title description 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 11
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 10
- 229940125721 immunosuppressive agent Drugs 0.000 claims abstract description 8
- 238000001802 infusion Methods 0.000 claims abstract description 7
- 229960000390 fludarabine Drugs 0.000 claims abstract description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims abstract description 5
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004562 carboplatin Drugs 0.000 claims abstract description 4
- 190000008236 carboplatin Chemical compound 0.000 claims abstract description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 4
- 229960001924 melphalan Drugs 0.000 claims abstract description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims abstract description 4
- 229960001196 thiotepa Drugs 0.000 claims abstract description 4
- 230000037396 body weight Effects 0.000 claims abstract description 3
- 239000000824 cytostatic agent Substances 0.000 claims abstract 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 7
- 238000011316 allogeneic transplantation Methods 0.000 claims description 4
- 210000002798 bone marrow cell Anatomy 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000002354 daily effect Effects 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 abstract description 10
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 17
- 229960002092 busulfan Drugs 0.000 description 16
- 239000013543 active substance Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000010322 bone marrow transplantation Methods 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UPYXKEAOXBAIFT-UHFFFAOYSA-N 3,4-dimethylazete-2-carboxamide Chemical compound CC1=C(C)C(C(N)=O)=N1 UPYXKEAOXBAIFT-UHFFFAOYSA-N 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 fluradabine Chemical compound 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19953517A DE19953517C1 (de) | 1999-11-05 | 1999-11-05 | Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation |
| PCT/EP2000/010871 WO2001032154A2 (de) | 1999-11-05 | 2000-11-03 | Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200200535A1 EA200200535A1 (ru) | 2002-10-31 |
| EA004543B1 true EA004543B1 (ru) | 2004-06-24 |
Family
ID=7928187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200200535A EA004543B1 (ru) | 1999-11-05 | 2000-11-03 | Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7199162B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1227808B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4846151B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE251455T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU777527B2 (cg-RX-API-DMAC7.html) |
| BG (1) | BG65845B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2389896C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ299701B6 (cg-RX-API-DMAC7.html) |
| DE (2) | DE19953517C1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA004543B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2208435T3 (cg-RX-API-DMAC7.html) |
| HU (2) | HU227332B1 (cg-RX-API-DMAC7.html) |
| NO (2) | NO329616B1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL212132B1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA73961C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001032154A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| JP7431815B2 (ja) * | 2018-09-26 | 2024-02-15 | メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク | トレオスルファンの結晶形 |
| PT4257122T (pt) | 2018-09-26 | 2026-06-08 | Medac Ges Fr Klinische Spezialprparate Mbh | Liofilizado de treossulfano |
| EP3856252A1 (en) | 2018-09-26 | 2021-08-04 | medac Gesellschaft für klinische Spezialpräparate mbH | Solution comprising treosulfan |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376546A (en) * | 1991-11-04 | 1994-12-27 | Xoma Corporation | Analogs of ribosome-inactivating proteins |
| DE4421391C1 (de) * | 1994-06-18 | 1995-11-30 | Gsf Forschungszentrum Umwelt | Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression |
| WO2000045842A2 (en) * | 1999-02-04 | 2000-08-10 | The General Hospital Corporation | Methods for human allografting |
-
1999
- 1999-11-05 DE DE19953517A patent/DE19953517C1/de not_active Expired - Lifetime
-
2000
- 2000-03-11 UA UA2002054343A patent/UA73961C2/uk unknown
- 2000-11-03 JP JP2001534359A patent/JP4846151B2/ja not_active Expired - Fee Related
- 2000-11-03 DE DE50004024T patent/DE50004024D1/de not_active Expired - Lifetime
- 2000-11-03 PL PL356240A patent/PL212132B1/pl unknown
- 2000-11-03 EA EA200200535A patent/EA004543B1/ru not_active IP Right Cessation
- 2000-11-03 ES ES00975995T patent/ES2208435T3/es not_active Expired - Lifetime
- 2000-11-03 CZ CZ20021562A patent/CZ299701B6/cs not_active IP Right Cessation
- 2000-11-03 AT AT00975995T patent/ATE251455T1/de not_active IP Right Cessation
- 2000-11-03 US US10/129,352 patent/US7199162B1/en not_active Expired - Lifetime
- 2000-11-03 AU AU13918/01A patent/AU777527B2/en not_active Expired
- 2000-11-03 CA CA002389896A patent/CA2389896C/en not_active Expired - Lifetime
- 2000-11-03 WO PCT/EP2000/010871 patent/WO2001032154A2/de not_active Ceased
- 2000-11-03 HU HU0203277A patent/HU227332B1/hu active Protection Beyond IP Right Term
- 2000-11-03 EP EP00975995A patent/EP1227808B1/de not_active Expired - Lifetime
-
2002
- 2002-05-02 NO NO20022109A patent/NO329616B1/no not_active IP Right Cessation
- 2002-06-04 BG BG106772A patent/BG65845B1/bg unknown
-
2019
- 2019-07-23 NO NO2019032C patent/NO2019032I1/no unknown
- 2019-09-18 HU HUS1900041 patent/HUS1900041I1/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2389896A1 (en) | 2001-05-10 |
| ATE251455T1 (de) | 2003-10-15 |
| CZ20021562A3 (cs) | 2002-10-16 |
| BG65845B1 (bg) | 2010-03-31 |
| EP1227808B1 (de) | 2003-10-08 |
| NO2019032I1 (no) | 2019-07-23 |
| DE50004024D1 (de) | 2003-11-13 |
| EP1227808A2 (de) | 2002-08-07 |
| CZ299701B6 (cs) | 2008-10-22 |
| AU1391801A (en) | 2001-05-14 |
| WO2001032154A2 (de) | 2001-05-10 |
| DE19953517C1 (de) | 2001-08-09 |
| NO20022109L (no) | 2002-07-01 |
| US7199162B1 (en) | 2007-04-03 |
| PL212132B1 (pl) | 2012-08-31 |
| NO329616B1 (no) | 2010-11-22 |
| ES2208435T3 (es) | 2004-06-16 |
| AU777527B2 (en) | 2004-10-21 |
| HUP0203277A2 (en) | 2003-01-28 |
| PL356240A1 (en) | 2004-06-28 |
| BG106772A (bg) | 2003-02-28 |
| NO20022109D0 (no) | 2002-05-02 |
| CA2389896C (en) | 2007-04-10 |
| UA73961C2 (uk) | 2005-10-17 |
| WO2001032154A3 (de) | 2002-01-24 |
| JP2003513034A (ja) | 2003-04-08 |
| JP4846151B2 (ja) | 2011-12-28 |
| EA200200535A1 (ru) | 2002-10-31 |
| HU227332B1 (en) | 2011-03-28 |
| HUS1900041I1 (hu) | 2019-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Inamura et al. | Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK 506 | |
| US12343342B2 (en) | Methods for treating soft tissue sarcoma | |
| EP0344880B1 (en) | Pharmaceutical compositions with anti-cancer activity | |
| CN100479814C (zh) | 促淋巴细胞归巢剂在制备用于治疗移植物功能恢复延迟的药物中的用途 | |
| DE69124380T2 (de) | Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten | |
| US7199162B1 (en) | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation | |
| EP0972519B1 (en) | Immune tolerance inducers | |
| JP3962097B2 (ja) | 免疫抑制剤による副作用の軽減剤 | |
| JP2007527851A (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| JP3064815B2 (ja) | ミエローマ系腫瘍抗癌剤 | |
| Wilson et al. | Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma | |
| JPH09506115A (ja) | 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物 | |
| CN102614180A (zh) | 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用 | |
| KR100318519B1 (ko) | 우라실을 유효성분으로 함유하는 관절염치료제 | |
| RU2123348C1 (ru) | Противолучевое средство | |
| Veys et al. | Recombinant interferon gamma in rheumatoid arthritis. A double-blind study comparing Immuneron (recombinant interferon gamma) with placebo | |
| JPH04327541A (ja) | 拒絶反応による移植臓器障害治療剤 | |
| JP2800412B2 (ja) | 免疫抑制作用増強剤 | |
| KR20220082862A (ko) | 혈액 악성 종양을 치료하기 위한 병용 요법 | |
| EP0784976A1 (en) | Immunosuppressive-activity potentiating compositions containing ascorbyl tocopheryl phosphoric acid diesters | |
| Taguchi et al. | Combination effect of human recombinant TNF (PT-050) and antitumor drugs | |
| Muller | The Influence of Liver Extract and Acute Infection on Reticulocytes and Bone Marrow of Pigeons | |
| Kurtzberg et al. | Results of the cord blood transplantation study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with inborn errors of metabolism | |
| Kohn et al. | Busulfan dose escalation to increase gene marking of hematopoietic stem cells by lentiviral vectors in infant rhesus monkeys | |
| WO1990001319A1 (en) | Use of castanospermine as an anti-inflammatory and immunosuppressant agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |